Enhanced with market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, The Business Research Company’s 2026 market reports deliver more actionable and strategically valuable research.

Computed Tomography (CT)-Guided Biopsy Market Size, Value And Growth Trends Through 2030

The computed tomography (CT)-guided biopsy market size has seen robust growth in recent years. Forecasts indicate it will increase from $0.77 billion in 2025 to $0.82 billion in 2026, achieving a compound annual growth rate (CAGR) of 6.4%. During prior periods, this growth was primarily influenced by the escalating global incidence of cancer, the increasing embrace of imaging-based diagnostic methods, the expansion of radiology infrastructure within hospitals, a heightened preference for procedures that are minimally invasive, and the improved availability of CT imaging systems.

The computed tomography (CT)-guided biopsy market size is anticipated to experience substantial growth over the next few years, reaching $1.06 billion by 2030 at a compound annual growth rate (CAGR) of 6.6%. This expansion during the forecast period is fueled by several factors, including the escalating demand for early-stage cancer detection, the rising adoption of precision medicine-based diagnostics, the proliferation of outpatient diagnostic centers, a growing aging population requiring diagnostic interventions, and advancements in biopsy needle technologies and procedural safety. Key trends expected in the forecast period encompass the increasing embrace of minimally invasive diagnostic procedures for early and accurate disease detection, a rising demand for image-guided precision interventions in oncology and infection diagnosis, a growing preference for outpatient and ambulatory biopsy procedures to alleviate hospital burden, the expansion of interventional radiology departments improving access to CT-guided procedures, and an increasing focus on early cancer screening and tissue-based diagnostics in clinical workflows.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample_request?id=59321528&type=smp

Computed Tomography (CT)-Guided Biopsy Market Growth Drivers: What Factors Are Accelerating Expansion?

The growing occurrence of cancer is projected to stimulate the expansion of the CT-guided biopsy market. This rise in cancer cases is primarily attributed to an increasing elderly population, as older individuals face a greater likelihood of developing solid tumors necessitating accurate and timely diagnostic confirmation. CT-guided biopsy addresses this requirement by allowing for precise tissue collection from deeply located or anatomically intricate lesions, especially in organs such as the lung, liver, pancreas, kidney, and bone, where solely imaging methods are often insufficient for a definitive diagnosis and treatment strategy. For instance, in April 2024, data from the International Agency for Research on Cancer, a France-based intergovernmental organization that is part of the World Health Organization, indicated that there were approximately 20 million new cancer cases and nearly 10 million cancer-related deaths globally in 2022. Future demographic analyses suggest that the yearly count of new cancer cases is anticipated to reach 35 million by 2050, signifying a 77% rise compared to 2022. Consequently, the increasing incidence of cancer is propelling the growth of the CT-guided biopsy market.

Computed Tomography (CT)-Guided Biopsy Market Segmentation And Category Breakdown

The computed tomography (ct)-guided biopsy market covered in this report is segmented –

1) By Biopsy Technique: Core Needle Biopsy, Fine Needle Aspiration, Vacuum-Assisted, Trephine Or Bone

2) By Target Organ: Lung, Liver, Kidney, Bone, Pancreas, Other Target Organs

3) By CT Modality: Conventional CT, CT-Fluoroscopy, Cone-Beam CT, Spectral Or Dual-Energy CT

4) By Needle System: Coaxial Systems, Non-Coaxial, Semi-Automated, Fully Automated

5) By End User: Hospitals, Imaging Centers, Ambulatory Surgical Centers

Subsegments:

1) By Core Needle Biopsy: Automated Core Needle Biopsy, Image Guided Core Needle Biopsy, Coaxial Core Needle Biopsy, Single Use Core Needle Biopsy

2) By Fine Needle Aspiration: Image Guided Fine Needle Aspiration, Endoscopic Fine Needle Aspiration, Percutaneous Fine Needle Aspiration, Ultrasound Assisted Fine Needle Aspiration

3) By Vacuum-Assisted: Image Guided Vacuum-Assisted Biopsy, Stereotactic Vacuum-Assisted Biopsy, Ultrasound Guided Vacuum-Assisted Biopsy, High Volume Vacuum-Assisted Biopsy

4) By Trephine Or Bone: Bone Marrow Trephine Biopsy, Image Guided Bone Biopsy, Percutaneous Bone Biopsy, Orthopedic Bone Biopsy

Computed Tomography (CT)-Guided Biopsy Market Trends: What Is Shaping Future Industry Growth?

Major companies engaged in the CT-guided biopsy market are focusing on creating advanced navigation technologies, including real-time CT navigation systems, to improve procedural accuracy, lessen radiation exposure, and enhance workflow efficiency. Real-time CT navigation systems are integrated platforms for imaging and guidance that use 3D visualization and electromagnetic tracking to aid clinicians in precisely guiding biopsy needles to designated lesions, thereby minimizing the need for repeated imaging. For example, in April 2023, GE HealthCare, a US-based medical technology enterprise, launched its CT-Navigation solution. This system offers real-time 3D CT imaging for stereotactic needle guidance across various procedures such as biopsies, ablations, and drainage. It integrates electromagnetic navigation technology, which allows for complex needle trajectories, enabling clinicians to avoid critical anatomical structures. Moreover, the solution reduces radiation dose and procedure time by decreasing the necessity for multiple control scans while simultaneously improving targeting accuracy, thus boosting safety and efficiency in interventional procedures.

Computed Tomography (CT)-Guided Biopsy Market Competitive Analysis Of Major Industry Participants

Major companies operating in the computed tomography (ct)-guided biopsy market are Samsung Electronics, F. Hoffmann-La Roche AG, Thermo Fisher Scientific Inc., Stryker Corporation, Medtronic PLC, Boston Scientific Inc., Becton Dickinson and Company, Siemens Healthineers, Agilent Technologies Inc., GE HealthCare Technologies, Canon Inc., Zimmer Biomet Holdings Inc., Terumo Corporation, Fujifilm Corporation, Illumina Inc., Koninklijke Philips N. V., Olympus Corporation, Hologic Inc., Teleflex Incorporated, Sysmex Corporation, QIAGEN N. V., Bio-Rad Laboratories Inc., Shimadzu Corporation, Merit Medical Systems Inc., Guerbet (GBT. PA)

Access The Complete Computed Tomography (CT)-Guided Biopsy Market Report:

https://www.thebusinessresearchcompany.com/report/computed-tomography-ct-guided-biopsy-market-report

Computed Tomography (CT)-Guided Biopsy Market Geographic Analysis: Where Is Demand Growing The Fastest?

North America was the largest region in the CT-guided biopsy market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the computed tomography (CT)-guided biopsy market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model